Biotech Values

[poorgradstudent]

GTHX:

I don't know what has changed to bring up the EP response rate into the 60-70% range since the 52% reported in the Socinski trial that was cited in the presentation. I don't know if that's really something to be worried about or not.

I have a table of 12 trials going back to 2011 that I used to assess the trilaciclib data.

I think it's up to you whether or not you're comfortable with the GTHX data to date. I was not, but it wouldn't be the first time I'm wrong.